Fidelity Investments
DAWN

Fidelity Investments’s Day One Biopharmaceuticals DAWN Stock Holding History

Fidelity Investments’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$507K Sell
23,640
-5,693,368
-100% -$80.2M ﹤0.01% 3122
2025
Q4 		$53.3M Sell
5,717,008
-4,380,660
-43% -$36.6M ﹤0.01% 1415
2025
Q3 		$71.2M Sell
10,097,668
-1,245,031
-11% -$8.57M ﹤0.01% 1310
2025
Q2 		$73.7M Sell
11,342,699
-2,357,749
-17% -$16.2M ﹤0.01% 1241
2025
Q1 		$109M Buy
13,700,448
+812,981
+6% +$8.76M 0.01% 1060
2024
Q4 		$163M Buy
12,887,467
+5,475,087
+74% +$76.2M 0.01% 901
2024
Q3 		$103M Buy
7,412,380
+4,750,936
+179% +$67.8M 0.01% 1085
2024
Q2 		$36.7M Sell
2,661,444
-1,742,897
-40% -$25.5M ﹤0.01% 1434
2024
Q1 		$72.8M Buy
4,404,341
+436,175
+11% +$6.53M ﹤0.01% 1183
2023
Q4 		$57.9M Sell
3,968,166
-2,057,962
-34% -$24.9M ﹤0.01% 1232
2023
Q3 		$73.9M Sell
6,026,128
-1,533,775
-20% -$20M 0.01% 1097
2023
Q2 		$90.3M Sell
7,559,903
-1,012,280
-12% -$13.2M 0.01% 1040
2023
Q1 		$115M Sell
8,572,183
-430,128
-5% -$8.4M 0.01% 936
2022
Q4 		$194M Buy
9,002,311
+210,820
+2% +$4.32M 0.02% 698
2022
Q3 		$176M Buy
8,791,491
+1,964,917
+29% +$41.8M 0.02% 723
2022
Q2 		$122M Buy
6,826,574
+4,232,055
+163% +$43.7M 0.01% 890
2022
Q1 		$25.7M Sell
2,594,519
-235,834
-8% -$3.12M ﹤0.01% 1673
2021
Q4 		$47.7M Buy
2,830,353
+668,444
+31% +$13.7M ﹤0.01% 1438
2021
Q3 		$51.3M Sell
2,161,909
-150,541
-7% -$3.61M ﹤0.01% 1399
2021
Q2 		$52.7M Buy
+2,312,450
New +$48.2M ﹤0.01% 1400

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Fidelity Investments's DAWN Position: Q1 2026 in Review

Fidelity Investments reduced its Day One Biopharmaceuticals (DAWN) stake by 100% in Q1 2026, selling an estimated $80.2M and leaving 23,640 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

Fidelity Investments first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. The position peaked at $194M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Fidelity Investments held 23,640 shares of Day One Biopharmaceuticals worth $507K as of Q1 2026.
  • Fidelity Investments sold 5,693,368 Day One Biopharmaceuticals shares in Q1 2026, an estimated $80.2M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3122 holding.
  • Fidelity Investments first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Fidelity Investments's Day One Biopharmaceuticals position peaked at $194M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.